# Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

> **NCT01191034** · PHASE1,PHASE2 · TERMINATED · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.

## Key facts

- **NCT ID:** NCT01191034
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-08-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Completion after 2 patients then stop due to end of validity of vaccine peptide
- **Last updated:** 2019-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01191034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01191034, "Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01191034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*